Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Celyad Sa ADR (CYAD)

Celyad Sa ADR (CYAD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Initiatives For Development of Gamma Delta T Cell Therapies Driven by Large Number of Clinical Trials FinancialNewsMedia - Thu Jan 19, 2023

EQNX::TICKER_START (NASDAQ:TCBP),(NASDAQ:CRDF),(NASDAQ:CYAD),(NASDAQ:RIGL),(NASDAQ:AZN) EQNX::TICKER_END

TCBPW : 0.0060 (-38.14%)
AZN : 181.02 (+2.60%)
CYAD : 0.4700 (-11.10%)
TCBP : 0.5000 (-67.53%)
RIGL : 35.61 (-0.34%)
CRDF : 1.2500 (-3.85%)
Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction Business Wire - Tue Sep 20, 2022

Cellistic, the cell therapy development and manufacturing business of Ncardia BV, and Celyad Oncology (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development...

CYAD : 0.4700 (-11.10%)
Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights Globe Newswire - Fri Aug 5, 2022

Enrollment ongoing in Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory (r/r)...

CYAD : 0.4700 (-11.10%)
Celyad Oncology Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b Trial Globe Newswire - Mon Aug 1, 2022

MONT-SAINT-GUIBERT, Belgium, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company...

CYAD : 0.4700 (-11.10%)
Celyad Oncology to Announce First Half 2022 Financial Results and Host Conference Call Globe Newswire - Thu Jul 28, 2022

MONT-SAINT-GUIBERT, Belgium, July 28, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company...

CYAD : 0.4700 (-11.10%)

Barchart Exclusives

AMEN Properties Just Announced a 25% Dividend Increase. What This Means for the High-Yield Royalty Stock. Barchart - Tue Jun 23, 6:30PM CDT
AMEN Properties raised its quarterly dividend by 25% to $12.50 per share, pushing the annualized payout to $50.00 and offering investors a yield of around 10%. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.